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Background: International guidelines recommend that for NSTEMI, the timing of invasive 
strategy (IS) is a function of patient’s baseline risk. The extent to which this is delivered 
across and within healthcare systems is unknown. 
Methods: Data were derived from 137,265 patients admitted with an NSTEMI diagnosis 
between 2010-2015 in England and Wales. Patients were stratified into low, intermediate and 
high-risk in keeping with international guidelines. Time to IS was categorised into early (24 
hours), intermediate (25-72 hours) and late (>72 hours). Multivariable logistic regression 
models were used to identify independent predictors of guidelines recommended receipt of 
IS.  
Results:  There were 3,608 (2.6%) low, 5,037 (3.7%) intermediate and 128,621 (93.7%) 
high-risk patients. Guidelines recommended use of IS was significantly lower in high-risk 
(16.4%) compared to intermediate (64.7%) and low-risk (62.5%) groups. Both men and 
women in the low-risk category were almost twice as likely to receive early IS compared to 
high-risk men (28.9% vs 17%, p<0.001) and women (26.9% vs 15%, p<0.001). Women (OR 
0.91 95%CI 0.88-0.94), troponin elevation (OR 0.39 95%CI 0.36-0.43) and acute heart 
failure on admission (OR 0.65 95%CI 0.61-0.70) were strong negative predictors of receiving 
IS within recommended time in the high-risk group.  
Conclusion: Our study shows that IS for management of NSTEMI is not delivered according 
to international guidelines recommendations. Specifically, the disconnect between baseline 
risk and utility of IS increases with increasing risk and women achieve slower access than 
men to IS. 
Keywords: Invasive strategy, non-ST elevation acute myocardial infarction, timing, risk 


























1. Introduction:  
An invasive strategy in the form of coronary angiography (CA) followed by revascularisation 
where appropriate, is associated with reduced ischemic complications and shorter in-hospital 
stays in patients presenting with non-ST elevation acute myocardial infarction (NSTEMI) (1-
5). Current guidelines recommend that the timing of interventional management should be 
determined by baseline risk (6,7), with both the European Society of Cardiology (ESC) and 
American Heart Association / American College of Cardiology (AHA/ACC) guidelines 
advising early intervention (<24 hours) in patients meeting the high-risk criteria, whereas a 
period of medical management followed by invasive strategy within 25-72 hours is advised in 
patients with an intermediate-risk profile. Data from randomised control trials and condensed 
meta-analyses show improved survival in NSTEMI patients following an early invasive 
strategy compared to a later more conservative approach, particularly in high-risk patients 
such as those with GRACE risk-score >140 (8-10). However, the results from individual 
studies evaluating the optimal timing of invasive strategy in patients with different baseline 
risk profiles are inconsistent(1,8,11,12). Although the debate around the optimal timing of 
invasive strategy in NSTEMI continues, current guidelines have adopted a time sensitive 
approach that is risk profile dependent.  
Despite these guidelines, provision of invasive strategy in real world clinical practice is 
variable and often discrepant due to a variety of potential barriers (13-15). Given this variable 
practice and the perception that it is often discrepant with guidelines, we investigated the 
relationship between baseline risk and timing of access to invasive strategy in a large national 
population admitted with a diagnosis of NSTEMI in England and Wales. Specifically, we 
examined whether the timing of invasive strategy is related to this baseline risk as defined by 
the two major international guidelines and how this varies in different components of each 













based invasive strategy in women compared to men. Third, we studied independent predictors 
of receiving invasive strategy within the recommended time across all three risk groups.  
2. Methods:  
 
2.1 Study design  
Data for this study were obtained from MINAP (Myocardial Infarction National Audit 
Project), a comprehensive, national clinical registry of patients hospitalised with a diagnosis 
of AMI in England and Wales. There are over 120 data fields in MINAP, encompassing 
baseline characteristics, comorbidities, timing of presentation and invasive intervention, peri-
admission pharmacology, in-hospital outcome, diagnosis on discharge and receipt of 
secondary prevention treatment(16-18). Data collection is mandated by Department of Health 
across 235 acute hospitals in the National Health Service (NHS) and its management have 
previously been described(19).  
2.2 Study Population 
We included patients admitted with a diagnosis of NSTEMI in any of the 235 hospitals 
between 1
st
 January 2010 to 31
st
 December 2015. The discharge diagnosis of NSTEMI in the 
MINAP registry is determined by local clinicians according to presenting history, clinical 
examination, and the results of inpatient investigations in keeping with the consensus 
document of the Joint European Society of Cardiology and American College of 
Cardiology(20) Patients with missing information on age, gender, in-hospital mortality, 
timing of invasive strategy and those managed conservatively were excluded from the 
analysis (supplementary figure 1). This constituted a final cohort of 137,265 patients, which 
were then categorised into low, intermediate and high-risk groups as per ESC and AHA/ACC 
guidelines(6,7). MINAP variables which were mapped against each guideline risk 













factors, we also collected information on co-existing comorbidities, cardiac biomarkers, in-
hospital and discharge medications, in-hospital outcomes including all-cause mortality, 
cardiac mortality, re-infarction, major bleeding, receipt of PCI and receipt of CABG. MINAP 
doesn’t collect the calculated GRACE risk score as such, however, information available 
from variables within the dataset was used to calculate GRACE risk score which has been 
previously described and validated for use in this registry(21,22). Time to invasive strategy 
was calculated from time of admission to the hospital and time of coronary angiography or 
PCI, which was then categorised into early (within 24 hours), intermediate (within 25-72 
hours) and late (>72 hours) groups. Current ESC and AHA/ACC guidelines advocate an 
immediate invasive strategy within 2 hours in patients presenting with haemodynamic 
instability, life-threatening arrhythmia, or recurrent or refractory angina, acute heart failure, 
mechanical complications of AMI or recurrent dynamic ECG changes. By contrast, invasive 
strategy within 24 h is recommended for patients presenting with elevated troponin or 
ischaemic ST-wave or T-wave changes or a Global Registry of Acute Coronary Events 
(GRACE) risk score of more than 140 points. As the timing is not always captured in hours 
within the MINAP dataset, hence it was not possible to accurately ascertain the timing of 
invasive strategy up to two hours. Therefore, we merged the very high-risk into high-risk 
group as patients meeting any of these criteria would still be required to undergo an invasive 
strategy within 24 hours of admission.  
2.3 Ethical approval 
Secondary use of anonymised MINAP dataset for research purposes is authorised under NHS 
research governance arrangements and further supported under section 251 of NHS act 2006 
(NIGB: ECC1-06(d)/2011), which allows researchers to use patient information collected 
within the dataset for medical research without patient consent. Therefore, a formal ethical 













2.4 Statistical analysis 
Stata college station version 14.1 was used to perform all the statistical analyses for this 
study. Baseline characteristics were reported using numbers and percentages for categorical 
variables, or median and interquartile ranges for continuous variables across the three groups. 
Chi
 
square and Wilcoxon rank sum were used to make the comparisons across three groups, 
whereas proportion tests were used to test statistically differences in proportions. The missing 
information about each variable is provided in the supplementary table 2. We developed an 
imputation framework based on chained equations to account for missing data for each group 
characteristic variables. Age, gender, hospital catheter laboratory status, ethnicity, timing of 
invasive strategy and in-hospital all-cause and cardiac mortality were registered as regular 
variables in the imputations model whereas all other variables including body mass index 
(BMI), GRACE risk-score >140, troponin elevation, acute heart failure, cardiogenic shock, 
seen by cardiologists, left ventricular (LV) systolic function or congestive cardiac failure, 
ECG changes defined as ST depression or transient ST elevation, prior history of PCI, 
coronary artery bypass graft (CABG), heart failure, hypercholesterolemia, angina, 
cerebrovascular disease, peripheral vascular disease, chronic renal failure, diabetes, 
hypertension, smoking status, asthma/COPD, family history of coronary disease, use of 
warfarin, loop diuretics, aspirin, P2Y12 inhibitors, statin, ACE inhibitor, beta-blocker were 
imputed. For the intermediate-risk group, we excluded high-risk group characteristics such as 
troponin elevation, acute heart failure, ECG changes, cardiogenic shock and GRACE risk 
score >140 from the imputation model. Similarly, intermediate-risk characteristics were 
excluded from low-risk imputation models. Using these models, 10 imputed datasets were 
generated for each of the risk group which were used to perform all the analyses. 
Multivariable logistic regression models were used to study the independent predictors of the 













variables used in the multiple imputation models were used in the multivariable logistic 
regression models.  
3. Results:  
 
3.1 Baseline characteristics 
From a total of 137,265 patients, 3608 (2.6%) were categorised as low-risk, whereas 5,037 
(3.7%) and 128,621 (93.7%) were categorised as intermediate and high-risk respectively, 
according to both ESC and AHA/ACC guidelines. Typically, patients identified as low-risk 
were younger (61.4years vs 68years, p<0.001), more likely to be women (31.5% vs 29.8%, 
p<0.001) and less comorbid with lower prevalence of previous cerebrovascular disease (3.9% 
vs7.3%, p<0.001), peripheral vascular disease (2.6% vs 5.3%, p<0.001), hypertension (46.5% 
vs 55.9%, p<0.001), and asthma or COPD (12.5% vs 15.3%, p<0.001) compared to high-risk 
group (Table 1). Supplementary Table 3 compares the differences in the baseline 
characteristics, in-hospital and discharge pharmacology and outcomes amongst men and 
women across the three risk groups. In the low-risk group, there were 2,471 (68.5%) men and 
1,137 (31.5%) women. Compared to low-risk men, low-risk women had a higher prevalence 
of hypertension (44.9% vs 38.1%, p<0.001), history of asthma or chronic obstructive airway 
disease (16.2% vs 10.2%, p<0.001). Within the intermediate-risk group, men had higher 
incidence of previous PCI (51.8% vs 41.7%, p<0.001) and CABG (18.6% vs 8.9%, p<0.001) 
respectively. Finally, high-risk women were significantly older (72year vs 66 year, p<0.001) 
and were likely to have more adverse features on presentation in the form of higher 
prevalence of acute heart failure (9.3% vs 6.2%, p<0.001), GRACE risk score > 140 (48.0% 
vs 42.6%, p<0.001), chronic renal failure (6.1% vs 5.7%, p<0.001) and history of diabetes 













also less likely to receive secondary prevention medications on discharge in the form of 
aspirin, statins, ACE inhibitors and beta-blockers.  
3.2 Level of Compliance with guidelines  
Overall, only one in six patients (16.4%) in the high-risk group received invasive strategy 
within the recommended target time (<24 hrs), whilst invasive strategy was provided within 
the recommended time targets in 35.3% of the intermediate and 37.5% of the low-risk cohorts 
category respectively (Figure 1). Both men and women respectively, in the low-risk category 
were almost twice as likely to receive early invasive strategy (within 24 hours) compared to 
high-risk men (28.9% vs 17%, p<0.001) and women (26.9% vs 15%, p<0.001) (Figure 2). 
Women were also consistently less likely to receive invasive strategy within the 
recommended time points across all groups; low-risk (35.6% vs 38.3%, p=0.02) intermediate-
risk (33.0% vs 36.2%, p=0.03) and high-risk group (15.0% vs 17.0%, p<0.001) compared to 
men (Figure 2). Paradoxically, Women in the high-risk group also experienced greater 
delays: 51.2% of women were treated beyond 72 hours compared to 46.7% men. 
Major differences were observed in the timing of invasive strategy amongst patients with 
high-risk features as defined by ESC or AHA/ACC guidelines. Early invasive strategy within 
recommended time were most commonly used in patients presenting with cardiac arrest 
(49.8%) or cardiogenic shock (22.1%) but lesser proportion of patients with a GRACE score 
>140 (14.0%) or presenting with acute heart failure (11.8%) received invasive strategy within 
recommended target time (figure 3). Furthermore, women in high-risk group (cardiogenic 
shock, cardiac arrest, acute heart failure, ST depression on the ECG, elevated troponin and 
GRACE risk score >140) were consistently less likely to receive an appropriately early 
invasive strategy compared to men (Figure 3). In addition, subgroup analysis demonstrated 













(supplementary Figure 2). For example, women with history of diabetes (29.3% vs 35.0%, 
p=0.007) and congestive cardiac failure (23.2% vs 29.4%, p<0.001) were less likely to 
receive invasive strategy within 25-72 hours compared to men, whereas receipt of invasive 
strategy within recommended time frames were similar in women with history of chronic 
renal disease (29.6% vs 26.4%, p=0.2) and intermediate GRACE risk-score (38.9% vs 38.6%, 
p=0.8) compared to men.  
3.3 Independent predictors of guidelines compliance 
Independent predictors of attainment of invasive strategy within the recommended timeframe 
for high, intermediate and low-risk are reported in supplementary Table 4. In the high-risk 
group, presence of cardiogenic shock (OR 2.78 95%CI 2.28-3.39), ST-segment changes (OR 
1.67 95%CI 1.61-1.73) and cardiac arrest (OR 2.44 95%CI 2.24-2.64) were strong positive 
predictors of receiving invasive strategy with 24 hours. In contrast, troponin elevation (OR 
0.39 95%CI 0.36-0.43), acute heart failure on presentation (OR 0.65 95%CI 0.61-0.70) were 
associated with reduced odds of receiving invasive strategy within 24 hours. High-risk 
females (OR 0.91 95%CI 0.88-0.94) and increasing age in high-risk group (OR 0.98 95%CI 
0.986-0.988) were also least likely to receive invasive strategy within target time. High-risk 
patient presenting to hospital with onsite PCI facilities were almost twice as likely to receive 
invasive strategy within target times (OR 2.49 95%CI 2.43-2.63), where patients managed at 
hospital with diagnostic cardiac catheter laboratory facilities were less likely to achieve these 
targets (OR 0.75 95%CI 0.68-0.83). Finally, an admission on the weekend was associated 
with significant delay (0.49 95%CI 0.46-0.51) in receipt of invasive strategy within 
guidelines recommended time point in high-risk group compared to those admitted during the 
week 













Analysis of temporal trends showed an increase in uptake of invasive strategy in all groups, 
but with a greater proportional increase in low-risk women (22.9% to 41.9%, p<0.001), 
whereas high-risk women had the least increase from 11% to 19.3%, p<0.001 during the 
study period (supplementary Figure 3).  
4. Discussion 
 
In this analysis of nearly 140,000 NSTEMI patients from a national AMI registry, we report a 
significant disconnect between targets for timing of invasive strategy based upon baseline 
risk according to the guidelines. In our study population, over 90% of NSTEMI patients 
admitted within the United Kingdom are deemed to be high-risk according to ESC or 
AHA/ACC guidelines, and in this cohort the recommendation is for an early invasive strategy 
(within 24 hours). In reality, only one in ten such high-risk NSTEMI patients actually 
received invasive strategy within this target time. Paradoxically, patients in the lowest risk 
category were twice as likely to receive an early invasive strategy compared to high-risk 
patients. Finally, access to invasive strategy within guideline recommended time targets was 
significantly lower in women than men. Specifically, high-risk women were more likely to 
present with adverse baseline clinical characteristics, they were less likely to receive invasive 
strategy within the recommended time points compared to men.. In fact, our findings show a 
wide variation in adherence to guidelines, particularly amongst high-risk women.  
Current ESC guidelines around the management of NSTEMI recommend an early invasive 
strategy within 24 hours in patients with high-risk features on presentation such as rise or fall 
in cardiac troponin, dynamic ECG changes, and GRACE risk score >140, with an aim to 
offer invasive coronary angiography no later than 72hours in patients with intermediate-risk 
profile such as diabetes mellitus, renal disease, congestive cardiac failure, previous PCI or 













and time points for offering invasive strategy are similar to the ESC guidelines(7). Almost 
93% of the NSTEMI cohort in this study were deemed high-risk, in the majority of whom 
this was based upon them having at least one troponin level above the 99
th
 percentile. Both 
ESC and AHA/ACC guidelines recommend that at least one elevated troponin level above 
the 99
th
 percentile cut off is required to make diagnosis of NSTEMI. However, offering an 
early invasive strategy within 24 hours to patients meeting these criteria will have major 
resource implications for several reasons and is likely to require restructure of national ACS 
services. Firstly, condensed data from RCTs shows that only high-risk patients with GRACE 
risk score >140 benefit from an early invasive strategy and have better clinical outcomes 
whereas the optimal timing of invasive strategy in patients with other high-risk features such 
as troponin positive or ECG changes is less clear (8,12). Secondly, utilisation of increasingly 
highly sensitive troponin assays has resulted in increased detection of low-risk NSTEMI 
patients and concurrent fall in diagnosis of Unstable angina(23-25). Furthermore, the advent 
of highly sensitive troponin assays has facilitated the misinterpretation of apparently raised 
assay results to indicate Type 1 MI, when in fact the result may reflect Type 2 MI or 
myocardial injury(26). Although, rise or fall in cardiac troponin is important from a 
diagnostic point of view, optimal timing of intervention in this cohort requires further 
research. Therefore, mandating invasive strategy within 24 hours to such large proportions of 
patients would require a major expansion in service structure and delivery in an already 
stretched healthcare system. Further data is required to elucidate an optimal time of 
intervention in patients with different high-risk features as currently prescribed by guidelines. 
Our results show a clear disassociation between the recommendations for target times for 
invasive strategy access on one the hand and what is actually offered to patients on the other. 
We found a consistently lower real life use of invasive strategy in all risk groups. 













within a recommended time frame of 24 hours. More importantly, there was a significant 
risk-treatment paradox in that low and intermediate-risk patients were far more likely to get 
an early invasive strategy than those estimated to be at high-risk. This discrepancy may be 
explained by several factors such as treating physician bias, patient-related factors such as 
age, comorbidities and organisational factors such availability of onsite catheter lab 
facilities(27). In our analysis, we found that low-risk patients were almost three times more 
likely to receive invasive strategy when admitted to hospitals with onsite cardiac catheter 
laboratory facilities. Further efforts are required to develop a multifaceted approach in 
dissemination of guidelines, as well as to improve adherence and clinical care(15).  
Our striking observation in this analysis was around inequalities in receipt of appropriate, 
guidelines based invasive strategy amongst women and men. We found that women 
presenting with high-risk features were not only less likely to receive invasive strategy within 
recommended time points, but experienced greater delays compared to men. Furthermore, 
there was also significant heterogeneity in the application of a guidelines based invasive 
approach in women with an intermediate-risk profile. Disparities in cardiovascular care and 
outcomes amongst men and women are widely reported in the literature (28-31).The lower 
survival in women presenting with AMI is not entirely explained by the differences in their 
presentation, symptomology and comorbidities(32). Whilst previous studies have reported 
significant discrepancies in the use of coronary angiography amongst women(28,33), our 
study is the first one to highlight heterogeneity between use of invasive strategy and guideline 
prescribed risk criteria.  Our findings indicate that women are only more likely to experience 
biases in receipt of guidelines-based invasive strategy compared to men but this gender gap 
appears to be greater with increasing baseline risk amongst women. 













To best of our knowledge this is the first study to provide comprehensive illustration of real-
world practice of guidelines recommended invasive strategy amongst men and women in a 
single national healthcare system. However, certain limitations should be considered whilst 
interpreting our observations. A majority of our patients were in a high-risk group due to 
significant number of patients having positive cardiac biomarkers. We didn’t have 
information about dynamic changes in the cardiac troponin, instead we used the guideline 
recommended criteria of rise in cardiac troponin with at least one value above the 99
th
 
percentile. It is possible that some of these troponin rise may be related to type 2 MI for 
which the impetus for invasive strategy is less clear. We included patients with very high-risk 
features such as cardiogenic shock, cardiac arrest, acute heart failure and dynamic ECG 
changes into high-risk category. Current ESC and AHA/ACC guidelines actually recommend 
an immediate invasive strategy within 2 hours in these patients, but in this study we have had 
to include them in the group recommended to have invasive strategy within 24 hours.  
5. Conclusion:  
 
In this NSTEMI cohort, we found a significant disconnect between guidelines recommended 
risk and use of invasive strategy in clinical practice. Specifically, over two thirds of high-risk 
NSTEMI patient did not receive invasive strategy within guidelines recommended time 
points. There also appear to be significant sex-based inequalities in that women were not only 
more likely to experience higher delays in receipt of invasive strategy, women presenting 
with high-risk characteristics were significantly less likely to be treated invasively in the 
recommended time points compared to men. Future efforts need to focus around development 
of quality improvement programmes and educational interventions to promote uniform 
delivery of guidelines-based care in this cohort.  
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Table 1: Baseline Characteristics of patient stratified into low, intermediate and high-risk groups according to ESC and AHA/ACC guidelines 







Age ( Years) 61.4[52.4-70] 66[57-74] 68[58-77] <0.001 
Women (%) 1,137 (31.5%) 1,383 (27.5%) 38,291 (29.8%) <0.001 
Caucasians (%) 2,805 (77.7%) 3,592 (71.3%) 103,644 (80.6%) <0.001 
BMI median [IQR] 27.7 [24.9-31.0] 28.4 [25.4-3.6] 27.5 [24.5-31.1] <0.001 
high risk Characteristics     
Cardiogenic shock - - 463 (0.4%)  
ECG ST changes - - 34,288 (26.9%)  
Cardiac arrest - - 3,092 (2.5%)  
Acute heart failure - - 9,203 (7.2%)  
High risk GRACE score >140 - - 35,298 (44.2%)  
Troponin positive - - 125,070 (98.0%)  
Intermediate risk characteristics      
Intermediate risk GRACE score 
109-140 
- 1,423 (49.3%) 25,388 (31.9%) <0.001 
Chronic renal failure - 215 (4.4%) 7,148 (5.8%) 0.01 
Percutaneous coronary intervention - 2,426 (49.0%) 20,713 (16.8%) <0.001 
Coronary artery bypass graft - 789 (16.0%) 11,015 (8.9%) <0.001 
Diabetes - 2,106 (42.2%) 31,729 (25.0%) 0.001 
LVEF<40% or CCF - 837 (34.5%) 24,548 (35.7%) <0.001 
Other clinical characteristics      
Hypercholesterolemia 1,306 (43.5%) 2,904 (59.6%) 50,757 (41.7%) 0.10 












Cerebrovascular disease 119 (3.9%) 351 (7.2%) 9,019 (7.3%) <0.01 
Peripheral vascular disease 77 (2.6%) 219 (4.6%) 6,501 (5.3%) <0.001 
Hypertension 1,423 (46.5%) 3,224 (65.2%) 69,088 (55.9%) <0.001 
Smoking status     
Previous smoker 1,026 (33.0%) 2,064 (42.4%) 46,156 (37.1%) <0.001 
Current smoker 842 (27.1%) 846 (17.4%) 32,305 (26.0%) <0.001 
Asthma / COPD 378 (12.5%) 779 (15.9%) 18,776 (15.3%) <0.001 
Seen by cardiologist 3,367 (98.56%) 4,912 (98.8%) 126,664 (99.1%) 0.03 
Heart rate, bpm, median (IQR) 70 [61-80] 70 [60-80] 75 [65-88] <0.001 
Systolic blood pressure, median 
(IQR) 
140 [125-155] 138 [122-155] 140 [124-159] <0.001 
Family history  of CHD 1,191 (44.8%) 1,686 (39.2%) 38,970 (35.6%) 0.001 
Hospital catheter lab status     
No onsite laboratory  292 (8.1%) 319 (6.3%) 8,999 (7.0%) 0.01 
Onsite diagnostic laboratory  354 (9.8%) 457 (9.1%) 16,262 (12.6%)  
Onsite PCI laboratory  2,962 (82.1%) 4,261 (84.6%) 103,360 (80.4%)  
In-hospital Pharmacology     
Low molecular weight heparin 1,208 (41.5%) 2,129 (46.8%) 57,214 (50.8%) <0.001 
Warfarin 61 (2.2%) 245 (4.1%) 5,713 (5.2%) 0.001 
Loop Diuretic 196 (7.0%) 708 (15.9%) 22,529 (20.7%) <0.001 
Glycoprotein use 117 (4.1%) 188 (4.1%) 6,869 (6.2%) <0.001 
Discharge Medications     
Aspirin 2,920 (96.9%) 4,440 (96.9%) 110,412 (97.0%) 0.79 
P2Y12 inhibitors 3,098(94..1%) 4,673 (95.4%) 122,474 (96.9%) 0.001 
Statins 2,869 (96.5%) 4,396 (96.0%) 108,940 (96.6%) 0.04 
ACE inhibitors 1,619 (85.3%) 2,805 (89.3%) 69,293 (89.5%) <0.001 
Beta-Blockers 2,395 (83.7%) 3,785 (85.3%) 97,628 (87.2%) <0.001 
Crude outcomes     
Death 3 (0.1%) 6 (0.1%) 1,354 (1.0%) 0.001 
Cardiac mortality 1 (0.1%) 3 (0.1%) 1,125 (0.9%) 0.001 
Reinfarction 12 (0.4%) 33 (0.7%) 1,028 (0.8%) 0.01 












GRACE= Global Registry of Acute Coronary Events, CRF= chronic renal failure, PCI= percutaneous coronary intervention, CABG= coronary artery 














Figure legends:  
Figure 1: Overall proportion of patients receiving invasive strategy within guidelines 
recommended time frame according to their risk 
Figure 2: Proportion of Men and Women receiving invasive strategy within guidelines 
recommended time frame according to their risk 
Figure 3: Men, women and overall proportions in the high-risk group receiving invasive 
















 Invasive strategy in the management of patients admitted with NSTEMI is guided by 
their baseline risk. 
  Based on risk criteria of two international guidelines, over 90% of patients admitted 
with diagnosis of NSTEMI are high-risk.  
 Only one in ten of these high-risk patients received invasive strategy within the 
recommended time.  
 Paradoxically, both men and women with low-risk are twice as likely to receive early 
invasive strategy compared to high-risk men and women.  
Journal Pre-proof
Figure 1
Figure 2
Figure 3
